Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Seres Therapeutics (MCRB) Interest Expenses (2020 - 2024)

Seres Therapeutics' Interest Expenses history spans 5 years, with the latest figure at -$618000.0 for Q4 2024.

  • For Q4 2024, Interest Expenses changed N/A year-over-year to -$618000.0; the TTM value through Sep 2025 reached -$618000.0, down 200.0%, while the annual FY2023 figure was $2.5 million, 59.0% down from the prior year.
  • Interest Expenses for Q4 2024 was -$618000.0 at Seres Therapeutics, down from $618000.0 in the prior quarter.
  • Across five years, Interest Expenses topped out at $3.2 million in Q2 2023 and bottomed at -$2.7 million in Q3 2023.
  • The 5-year median for Interest Expenses is $738000.0 (2021), against an average of $842470.6.
  • The largest annual shift saw Interest Expenses skyrocketed 154.74% in 2022 before it plummeted 254.43% in 2023.
  • A 5-year view of Interest Expenses shows it stood at $759000.0 in 2020, then decreased by 2.77% to $738000.0 in 2021, then surged by 154.74% to $1.9 million in 2022, then crashed by 241.86% to -$2.7 million in 2023, then surged by 76.83% to -$618000.0 in 2024.
  • Per Business Quant, the three most recent readings for MCRB's Interest Expenses are -$618000.0 (Q4 2024), $618000.0 (Q1 2024), and -$2.7 million (Q3 2023).